Xydalba

Xydalba (dalbavancin) is an intravenous antibiotic used to treat serious bacterial infections. It belongs to the glycopeptide class and is administered in healthcare settings. Dalbavancin provides long-acting coverage against gram-positive bacteria.

Dalbavancin is used to treat infections caused by susceptible gram-positive bacteria, including skin and skin structure infections. It may also be used for other bacterial infections as prescribed by a healthcare provider. Dalbavancin is designed for intravenous use in clinical settings.

As an antibiotic, dalbavancin works by interfering with bacterial cell wall formation, leading to bacterial death. Patients may experience symptom improvement within days of administration. Common effects include reduced fever and localized infection signs.

Dalbavancin should only be handled and administered by trained healthcare professionals. Patients with known allergies to glycopeptide antibiotics should avoid this medication. Proper infection control measures should be maintained during administration.

Dalbavancin may interact with other medications that affect liver enzymes, though specific interactions are limited. Caution is advised when used with drugs known to prolong QT intervals. Always inform healthcare providers about all medications being taken.